StockData
Insight Molecular Diagnostics Inc. logo

Insight Molecular Diagnostics Inc. (IMDX) stock

IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$1.78−0.08 (-4.30%)

Close on Nov 17, 2026Market cap $58.25MP/E –Yield –

Earnings

Insight Molecular Diagnostics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 9, 2026
Q3 FY2026 · estimated, during market hours
Revenue, Q2 FY2026
–
Non-GAAP net loss per share, Q2 FY2026
-$0.23
-$0.30 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Insight Molecular Diagnostics's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 30, 2026Nov 9, 2026Expected–––––
Q2 FY2026ended Jun 30, 2026Aug 10, 2026during market hours––-$0.31-$0.23Release
Q1 FY2026ended Mar 31, 2026May 13, 2026during market hours––-$0.12-$0.28Release
Q4 FY2025ended Dec 31, 2025Mar 26, 2026during market hours$1.10M-26.7%––Release
Q3 FY2025ended Sep 30, 2025Nov 10, 2025during market hours––-$0.34–Release
Q2 FY2025ended Jun 30, 2025Aug 11, 2025during market hours––-$0.30–Release
Q1 FY2025ended Mar 31, 2025May 12, 2025during market hours$2.14M+1115.9%––Release
Q4 FY2024ended Dec 31, 2024Mar 24, 2025during market hours$1.50M–-$1.93–Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024during market hours––-$0.98–Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024during market hours$104.00K-79.2%-$0.36–Release
Q1 FY2024ended Mar 31, 2024May 15, 2024during market hours$176.00K-74.9%––Release
Q4 FY2023ended Dec 31, 2023Apr 12, 2024before the open––––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Insight Molecular Diagnostics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Insight Molecular Diagnostics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Insight Molecular Diagnostics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. News
  6. Update
  7. Results
  8. Results
  9. Update
  10. Update
  11. Results
  12. Results
  13. Update
  14. Results
  15. Update

See a number that looks wrong?